Tenet Healthcare’s Q3 2026 Run-Up: EBITDA Expands, Outlook Upbeat, and the “Ambulatory” Path Forward for THC
Ticker: THC. In this quarter’s filing, Tenet Healthcare Corporation reports notable progress on EPS metrics and revenue trajectory, with management lifting the revenue and cash-flow outlook for 2026. The numbers arrive with the context of a hospital-and-outpatient services mix that’s increasingly tilted toward ambulatory care—a structure that often carries higher visibility for earnings per share and margins.
Executive snapshot
Tenet, traded on the NYSE under THC, delivered a robust third quarter for 2026. Net income available to common shareholders reached $1.000 billion, translating to $12.41 per diluted share on a GAAP basis, versus $342 million and $3.86 per share in the third quarter of 2025. On an adjusted basis, diluted earnings per share rose 79.5% to $6.64, up from $3.70 in the prior-year period.
Consolidated Adjusted EBITDA climbed 23.3% to $1.355 billion, with an Adjusted EBITDA margin of 24.1%. The ambulatory care segment contributed $537 million in Adjusted EBITDA, up 9.1% year over year.
Key financials
- Net operating revenues for the quarter: $5,631 million, up from $5,289 million in the prior-year period.
- Three months ended Sept. 30, 2026 vs Sept. 30, 2025 comparisons show meaningful top-line growth alongside disciplined cost management.
- FY 2026 outlook updated: Adjusted EBITDA now expected to be in the $5.05 billion to $5.20 billion range (midpoint about $5.125 billion), a $195 million uplift at the midpoint.
- FY 2026 Adjusted Free Cash Flow outlook raised to $2.825 billion to $3.125 billion, a $100 million increase at the midpoint.
Management commentary
“Our outperformance in the third quarter of 2026 was driven by sustained strength in same-store revenue growth and effective expense management,” said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. “Our focus on patient-centered care, support for physician partners, technology-enabled growth and operating initiatives continue to deliver strong margins and free cash flow.”
The tone suggests a persistent emphasis on efficiency and scale within Tenet’s outpatient and acute-care mix. The numbers point to a combination of ongoing revenue growth (likely in same-store volumes) and operating leverage from cost controls that support higher adjusted profitability and cash generation—even as the GAAP bottom line shows a substantial uplift due to the quarter’s revenue mix and non-GAAP adjustments.
Outlook and implications
The revised 2026 guidance implies Tenet remains confident in continued earnings power and cash flows, even as it navigates a hospital- and ambulatory-care landscape that faces evolving payer dynamics and regulatory considerations. The adjusted EPS of $6.64 in Q3 2026 represents a strong YoY rise, and the continuation of double-digit EBITDA growth signals a potential resilience in profit margins amidst growing outpatient volumes.
For investors, the mix shift toward ambulatory care is meaningful. If that segment sustains its growth trajectory, Tenet could fare relatively well against peers that rely more on inpatient hospital admissions, where reimbursement pressure and volume volatility can weigh on quarterly results.
Sectorwide perspective
Tenet’s results may ripple through hospital and healthcare services signaling a broader investor appetite for genetics of growth in outpatient networks. Peers such as large multispecialty networks and hospital operators will be watching whether Tenet’s margin expansion and cash-flow accretion persist as payer mixes and labor costs evolve. The earnings narrative—strong EPS delivery, a meaningful earnings surprise potential, and a raised revenue forecast for the year—could recalibrate how the sector prices growth in the near term.
Numbers at a glance and takeaways
In the quarter, GAAP net income rose sharply, but the more relevant investor lens often centers on Adjusted EPS and Adjusted EBITDA, given the company’s ongoing use of non-GAAP measures to illustrate operating performance. The reported EPS of $12.41 per diluted share on a GAAP basis versus adjusted EPS of $6.64 highlights the usual gap between reported net income and the earnings that management deems core to ongoing operations. The revenue trajectory, with net operating revenues of $5.631 billion for the quarter, supports the identified path to higher cash generation and a stronger balance sheet.
The guidance lift, particularly the $5.05–$5.20 billion Adjusted EBITDA range and $2.825–$3.125 billion in Adjusted Free Cash Flow, is the clearest signal that management expects more efficient use of capital, notwithstanding the usual industry sensitivities around reimbursement and staffing costs.
Final take
Tenet’s Q3 2026 narrative is a reminder that in healthcare services, the denominator problem—how fast revenue grows in the outpatient channel versus the cost structure—matters as much as the numerator. The numbers suggest Tenet has found a revenue mix that scales well, and a cost discipline that translates revenue into free cash flow with fewer gyrations than some peers. If the ambulatory care momentum persists and the industry backdrop remains supportive, THC could see its earnings power reflected not just in a single quarter’s beat but in a more durable margin profile across the next year. In terms of the SEO-friendly markers readers watch for—ticker THC, EPS, earnings surprise, EPS consensus, and revenue forecast—Tenet’s Q3 report nudges the conversation toward a healthier, cash-creating growth story rather than a one-off earnings flare.